Cell Therapy
Pubblicato il 06-10-2026 - Biotecnologie - Farmacia - Chimica in Italia
Are you ready to turn cutting-edge cell therapy science into real-world trial performance and meaningful patient impact?
As the field-facing scientific and clinical expert, you will accelerate study execution and retention, sharpen safety practices, and enable early insight generation that shapes how we run our trials. Your work will translate complex protocols into practical, consistent actions across diverse sites and indications, driving measurable improvements in feasibility, start‐up, and conduct.
You will collaborate closely across functions to advance a bold pipeline with speed and quality, connecting therapeutic innovation to the day‐to‐day realities of study teams and trialists. Picture yourself guiding trialists through the cell therapy patient journey, elevating site performance, and transforming field insights into decisions that improve how we design, run, and scale studies. How would you turn evidence into action and help trial sites deliver with clarity and confidence?
Accountabilities
Cell Therapy Expertise:
Build and continuously maintain deep knowledge across indications and assets; be the go‐to expert who shapes guidance, training, and best practices that raise execution quality and consistency.
Strategic Communication: Lead clear, compliant communications that convey strategy, portfolio breadth, and product differentiation; align messaging across regions to ensure consistency for assigned protocols and sites.
Site Readiness and Training: Support and deliver site initiation content and advanced protocol education; implement competency‐based training to drive readiness, shorten start‐up timelines, and improve protocol adherence.
Enrollment Optimization: Translate inclusion/exclusion criteria and patient flow into pragmatic site actions that raise enrolment rates, reduce screen failures, and minimize attrition.
Insight Generation and Continuous Improvement: Capture and synthesize field insights on feasibility, bottlenecks, and patient pathways; supp